• Pseudo-UTP: Designing Better Modified mRNA Assays

  2026-09-16

  Pseudo-UTP enables controlled mRNA synthesis with pseudouridine modification, but its value depends on how RNA quality, translation, and reverse-transcription assays are designed. This guide presents an evidence-based framework for distinguishing nucleotide effects from workflow artifacts in vaccine and gene therapy research.

• SGC-CBP30 in LUAD Epigenetic Workflows

  2026-09-16

  SGC-CBP30 enables reversible testing of CREBBP/EP300 bromodomain dependence in super-enhancer and TGF-β/SMAD3 experiments. This guide translates findings from early-stage lung adenocarcinoma research into practical dose-response, chromatin, reporter, and troubleshooting workflows.

• TRIM66 and Monogenic Olfactory Receptor Choice

  2026-09-15

  This study identifies TRIM66 as an epigenetic repressor that helps convert early, low-level expression of multiple olfactory receptor genes into the mature one-neuron-one-receptor state. Genetic loss of Trim66 disrupts receptor repression, neural activity, and innate olfactory behaviors, linking enhancer control to sensory function.

• gamma-Glu-Cys: Designing Better Redox Assays

  2026-09-15

  Discover how gamma-Glu-Cys supports matrix-aware glutathione metabolism research, enzyme assays, and phytochelatin studies. This guide connects defined substrate selection with findings from Bacillus γ-glutamyl peptide research to improve experimental interpretation.

• EZ Cap™ Firefly Luciferase mRNA (m1Ψ) Workflow

  2026-09-14

  Build a quantitative reporter workflow that separates mRNA delivery, translation, cell health, and signal kinetics. EZ Cap™ Firefly Luciferase mRNA (m1Ψ) also provides a practical benchmark for evaluating emerging transient-expression platforms, including the circular mRNA strategy reported in recent CAR-T research.

• Protoporphyrin IX for Ferroptosis Workflows

  2026-09-14

  Build more interpretable photodynamic, heme-formation, and ferroptosis assays with Protoporphyrin IX. This workflow separates light-dependent activity from iron-handling biology and translates the METTL16-SENP3-LTF findings into practical experimental controls.

• SAG in Frataxin-Deficient Astrocytes

  2026-09-13

  Vicente-Acosta and colleagues show that chronic Smoothened agonist treatment can reduce mitochondrial defects, reactive astrocyte features, and neuron toxicity caused by frataxin depletion. The study provides a mechanistic preclinical framework for examining Hedgehog pathway activation as a glia-focused strategy in Friedreich’s ataxia research.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-12

  The reference study developed chemically modified CDKN1A/p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its molecular, cellular, biodistribution, and orthotopic mouse data indicate that local p21 restoration can suppress tumor growth while limiting systemic exposure, although clinical translation remains dependent on formulation, dosing, and human validation.

• Murine RNase Inhibitor for RNA Workflows

  2026-09-11

  Murine RNase Inhibitor provides targeted RNA degradation prevention for RT-PCR, cDNA synthesis, in vitro transcription, and labeling workflows, including assays that cannot tolerate high DTT. Its selectivity for pancreatic-type RNases and oxidative stability help researchers protect RNA without treating it as a universal nuclease blocker.

• DiscoveryProbe FDA-approved Drug Library for HTS

  2026-09-11

  A practical guide to using a clinically annotated compound collection for oncology screening, combination testing, and pharmacological target identification. Learn how to convert library hits into defensible mechanistic leads while avoiding misleading metabolic-assay signals.

• DiscoveryProbe Immunology/Inflammation Compound Library

  2026-09-10

  Turn a 295-compound collection into a multiparametric PBMC screening workflow that separates immune modulation from nonspecific toxicity. The approach combines target-oriented controls with proliferation, activation, and B-cell costimulatory readouts for more actionable inflammation research.

• Cimetidine: H2 Biology Meets BBB Assays

  2026-09-10

  Cimetidine is more than a conventional histamine-2 receptor antagonist: its partial H2 receptor pharmacology creates a useful probe for separating receptor biology from barrier transport. This article translates a modern BBB surrogate model into practical assay decisions for cancer research and gastrointestinal pharmacology.

• BV6 IAP Antagonist: Workflow for Apoptosis Studies

  2026-09-09

  BV6 provides a practical way to interrogate IAP-dependent survival, apoptosis induction in cancer cells, and therapy sensitization across cell and animal models. This workflow combines dose-response design with orthogonal pathway and phenotype readouts, while using the reference study to prevent overinterpreting caspase or mitochondrial signals.

• Sulfo-NHS-SS-Biotin: Practical Labeling Guide

  2026-09-09

  Sulfo-NHS-SS-Biotin is a water-compatible reagent for labeling primary amines on proteins and cell-surface molecules, with a disulfide linker that supports downstream cleavage by reducing agents. It is appropriate for fresh aqueous labeling workflows and affinity capture, but should not be stored after dissolution or exposed to reducing conditions before biotin-dependent purification.

• N1-Methylpseudo-UTP for Translational RNA

  2026-09-08

  N1-Methyl-Pseudouridine-5'-Triphosphate is more than a substituted uridine building block: it is a design variable for balancing RNA stability, innate immune visibility, translation, and analytical confidence. This thought-leadership article connects mechanistic evidence with practical in vitro transcription decisions and translational strategy.

636 records 1/43 page Next 12345 下5页 Last page